Beautiful Virgin Islands

Monday, Oct 06, 2025

The co-founder of BioNTech designed the coronavirus vaccine it made with Pfizer in just a few hours over a single day

The co-founder of BioNTech designed the coronavirus vaccine it made with Pfizer in just a few hours over a single day

BioNTech co-founder Ugur Sahin designed 10 different vaccine candidates over a single day in January. The FDA authorized one of them on Friday.

The Food and Drug Administration granted emergency authorization to Pfizer and BioNTech's coronavirus vaccine on Friday.

The two-dose vaccine is the first to be authorized in the US, though Moderna's coronavirus vaccine will likely receive FDA authorization this month as well.

After months of testing, the vaccine was found to be 95% effective in preventing COVID-19 in a large-scale trial. Its development process was unprecedentedly fast — no other vaccine in history has been created and manufactured so quickly. Previously, the fastest vaccine ever developed took more than four years.

But perhaps most remarkably, BioNTech co-founder Ugur Sahin designed the vaccine in just a few hours in mid-January, according to The Journal, a podcast from Gimlet and The Wall Street Journal.

A BioNTech spokesperson confirmed to Business Insider that Sahin — who founded the company with his wife, Özlem Türeci — made a "rough design over one weekend."

Moderna's vaccine also took just two days to design, as Business Insider previously reported. The reason both candidates could be designed so quickly comes down to the technology they rely on: messenger RNA, or mRNA.

The FDA had never approved an mRNA-based vaccine or treatment before. But now that the agency has granted authorization to Pfizer and BioNTech — with Moderna's likely to follow shortly — mRNA vaccines could set a new industry standard.

How mRNA vaccines train the body to fight the coronavirus


Messenger RNA is genetic material that tells cells how to make proteins. Pfizer's coronavirus vaccine candidate works by injecting a small piece of coronavirus mRNA into the body. That RNA codes for the virus' spike protein, which is what helps it attach to and invade cells. That's also what antibodies target and neutralize.

So the mRNA vaccine spurs the body to produce the spike protein internally in order to trigger that same immune response.

Moderna's candidate works in the same way and has been found to be 94.5% effective in trials.

Utilizing mRNA vaccine technology meant BioNTech and Moderna only needed the coronavirus' genetic sequence to design a vaccine. That's why they could move forward so quickly.

How BioNTech and Pfizer joined forces

The Pfizer facility in Pleasant Prairie, Wisconsin, on December 1, 2020.


On January 24, Sahin read a paper in The Lancet that described Chinese family members who traveled to Wuhan then contracted COVID-19.

"What was most concerning is that one of the family members had the virus and was virus-positive but did not have symptoms," Sahin told The Journal. This meant that the virus could be transmitted by asymptomatic carriers — and had probably already spread out of China.

"The math behind it just showed me it will happen, it's just a matter of a few weeks," Sahin said.

He decided to shift BioNTech's focus toward a coronavirus vaccine. The following week, Sahin told the company that operations going forward would be devoted mostly to developing and testing the vaccine.

Using the coronavirus' genetic sequence, which Chinese researchers published on January 11, Sahin designed 10 different candidates on his computer that weekend. One was the candidate later selected for larger trials — the one the FDA has authorized.

Sahin designed that winning candidate in just a few hours, according to The Journal.

But BioNTech, with a pre-pandemic workforce of 1,000, didn't have the capacity to manufacture the hundreds of thousands of doses needed for large-scale trials — let alone the hundreds of millions it would need if the vaccine worked.

So in February, Sahin called Pfizer's head of vaccine research, Kathrin Jansen; BioNTech had worked with Pfizer since 2018 on a flu vaccine.

"This is a disaster, and it's getting worse," Dr. Jansen told Dr. Sahin, according to The Wall Street Journal. "Happy to work with you."

The two companies announced their partnership in mid-March.


Kathrin Jansen, Pfizer's head of vaccine research and development.


Pfizer would manage the logistics, including manufacturing the vaccine in large batches and organizing the Phase 3 trial, which wound up involving 43,500 volunteers. BioNTech, meanwhile, handled the vaccine's design.

Pfizer and BioNTech announced that their vaccine was more than 90% effective on November 9. When Pfizer CEO Albert Bourla told told senior company officials of the findings, people jumped up from their chairs, The Wall Street Journal reported.

The full results of the Phase 3 trial were even stronger: The findings, published in the New England Journal of Medicine on Thursday, suggest that the vaccine doesn't trigger severe side effects in most people and is 95% effective at preventing COVID-19.

Anthony Fauci, the nation's leading infectious-disease expert, called the results "just extraordinary" and said they would "have a major impact on everything that we do with regard to COVID."

The speed at which BioNTech and Pizer developed the vaccine does not mean they sacrificed thoroughness, according to Albert Rizzo, chief medical officer for the American Lung Association.

"We're not skipping steps — we actually have better technology," Rizzo previously told Business Insider. "Why did it take two weeks to cross the Atlantic back in the 1800s? Well, we had to go on a boat. Whereas now, you can get across the ocean in several hours."

The pros and cons of mRNA vaccines


For decades, vaccines contained a dead or weakened version of a virus itself. Then early advances in genetics allowed vaccines to use proteins made by the virus instead. That method was first used in the 1980s to develop a vaccine for hepatitis B. Companies like Novavax are relying on the same protein-based model to create their coronavirus vaccine candidates.

But BioNTech was founded on the idea that mRNA could be used to develop cancer vaccines, hence its mRNA-based approach to the coronavirus. One of the company's senior vice presidents, biochemist Katalin Karikó, first discovered how to configure mRNA to be used in vaccines.


A volunteer receives an injection during South Africa's first human clinical trial for a potential vaccine against the coronavirus, at Baragwanath Hospital in Soweto, June 24, 2020.


Since RNA vaccines aren't cultivated using cells, they're quicker to produce.

The drawbacks of Pfizer and BioNTech's vaccine, however, are that people must get two injections three weeks apart, and it needs to be shipped at about -94 degrees Fahrenheit. That requires dry ice and special freezers.

Crucial questions about the vaccine also remain, like how long it will protect people from COVID-19 and whether it can prevent transmission and asymptomatic infection.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Munich Airport Reopens After Second Drone Shutdown
France Names New Government Amid Political Crisis
Trump Stands Firm in Shutdown Showdown and Declares War on Drug Cartels — Turning Crisis into Opportunity
Surge of U.S. Billionaires Transforms London’s Peninsula Apartments into Ultra-Luxury Stronghold
Pro Europe and Anti-War Babiš Poised to Return to Power After Czech Parliamentary Vote
Jeff Bezos Calls AI Surge a ‘Good’ Bubble, Urges Focus on Lasting Innovation
Japan’s Ruling Party Chooses Sanae Takaichi, Clearing Path to First Female Prime Minister
Sean ‘Diddy’ Combs Sentenced to Fifty Months in Prison Following Prostitution Conviction
Taylor Swift’s ‘Showgirl’ Launch Extends Billion-Dollar Empire
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
×